biotech / news / / South China Morning Post
More than 10 loss-making biotechnology companies have filed for Hong Kong stock exchange listings.
Over 10 unprofitable biotech firms have filed for Hong Kong listings in 2024.
KEY POINTS
- Hong Kong's healthcare and biotech equity capital market activity hit US$15.6 billion in 2023.
- Diagens Biotechnology's AI platform reduces genetic analysis from 30 days to 4-7 days.
- Diagens expects Chinese regulatory approval in Q1 and plans to seek FDA approval in April.
COMPANIES
Summarized by Newsio from South China Morning Post. How we summarize →